Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
18 participants
OBSERVATIONAL
2021-04-22
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Apatinib in Recurrent or Recurrent High-grade Glioma
NCT03390062
Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas
NCT04253873
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
NCT04588987
Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
NCT04501705
TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT
NCT03741244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
effective group
After treatment, tumor achieved complete response or partial response and the progression-free survival time was ≥6 months.
genetic characteristic
the underlying genetic characteristics that prodicting response
stable group
After treatment, tumor remains stable and the progression-free survival time was more than 1 month and less than 6 months.
genetic characteristic
the underlying genetic characteristics that prodicting response
Early progressed group
After treatment, tumor got progressed and the progression-free survival time was no more than 1 month.
genetic characteristic
the underlying genetic characteristics that prodicting response
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
genetic characteristic
the underlying genetic characteristics that prodicting response
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. recurrent glioblastoma
3. received apatinib plus temozolomide treatment，response and survival data were available
4. tumor tissues were acquired
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Sanbo Brain Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Junping Zhang
Chief physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Capital Medical University Sanbo Brain Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021ZZLX03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.